HELSINKI, Finland, June 2021. Euformatics, a bioinformatics software company providing world-leading NGS interpretation and quality control tools, has expanded its network of European distribution partners in an agreement with Polish distributor Analityk Genetyka.

The agreement brings the omnomics Suite of products to Polish NGS laboratories, including the CE-marked omnomicsNGS for variant interpretation and reporting, as the most advanced sample quality control tool on the market omnomicsQ, and omnomicsV for quick and easy gene test validation and verification.

The announcement follows several other recent distributor announcements for Euformatics and highlights the firm’s drive to grow the international customer base for its products substantially during 2021.

As the use of NGS technologies continues to expand at an exponential rate, the need for quality software tools to help manage the large amounts of data created becomes ever more imperative. The team behind the deal has effectively built the Polish NGS market together with Illumina since having an exclusive distribution partnership in place between the sequencer manufacturer and Analityk since 2012. The companies can now jointly target the significant installed base of Polish Illumina customers who are looking to benefit from advanced bioinformatics solutions to simplify their processes and make genetic diagnostics a much less time-consuming task.

“Ensuring that our customers are able to get the most out of their sequencing is really important to us. omnomicsNGS is an ideal tool for making NGS analyses quickly and reliably through a safe and secure platform. We are working with customers who know what they are doing and who need to save time as NGS-based diagnostics become mainstream. Through integrating omnomicsQ into their pipelines using the BaseSpace app they can automatically ensure that each sample they run is of the highest quality before it reaches interpretation. For clinical laboratories in Poland, we are convinced that the omnomics Suite offers the best functionality and quality for their NGS analysis needs” comments Juliusz Unrug, Analityk Genetyka Head of Marketing and Market Access.

Euformatics CEO Tommi Kaasalainen

“We have already been impressed with the depth and breadth of knowledge the team at Analityk Genetyka has for NGS technologies and are sure that this expertise will be instrumental in our shared success in Poland. As the market for NGS continues to grow we need to ensure that our partners share our determination to accelerate the transition to precision medicine and have the experience and knowledge to succeed. We are delighted to start this partnership and look forward to working with them to help provide high-quality software tools for NGS laboratories in the market” adds Euformatics CEO, Tommi Kaasalainen.

The agreement strengthens Euformatics’ commitment to providing NGS software tools to clinical laboratories globally as the uptake of NGS technologies continues to grow.

About Analityk Genetyka:

ANALITYK Genetyka was founded in 2018 as a direct continuation of former OpenExome (2012-2018). The company from the very beginning closely cooperates with ANALITYK, Illumina channel partner in Poland. Both companies ANALITYK Genetyka and ANALITYK offer wide portfolio of instruments, reagents and software used in Next Generation Sequencing (NGS). Our goal is to deliver best in class, comprehensive, end-to-end solutions to fully satisfy our customers’ needs. Many years of experience, deep understanding of Polish NGS market as well as strong cooperation with our foreign partners are key drivers to our success.

For more information, please visit our website

About Euformatics:

Euformatics is a Finnish software company that specialises in high standard bioinformatics tools for genomic data interpretation. Since 2010, Euformatics has been helping medical doctors and molecular genetics laboratories provide better precision medicine for cancer, common or rare disease diagnostics. At present, our core solution is the omnomics Suite which includes omnomicsNGS; for clinical analysis and reporting of patient NGS data, and omnomicsQ; for NGS data quality management.

For more information, please visit our website

Press relations:

Jamie McDonald

Juliusz Unrug
Analityk Genetyka

Back to news listing